section name header

Indications

High Alert


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: bradycardia, edema, QT interval prolongation, chest pain

Derm: rash

EENT: visual disturbances

Endo: testosterone

GI: liver enzymes, constipation, diarrhea, nausea, stomatitis, vomiting, appetite, abdominal pain, esophagitis, HEPATOTOXICITY

GU: fertility, renal impairment

Neuro: dysgeusia, fatigue, headache, insomnia, neuropathy

Resp: INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS

Misc: fever

Interactions

Drug-drug:

Drug-Natural Products:

Drug-Food:

Availability

Route/Dosage

Non-Small Cell Lung Cancer

Renal Impairment

Hepatic Impairment

Systemic Anaplastic Large Cell Lymphoma

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Inflammatory Myofibroblastic Tumor

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Renal Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

Hepatic Impairment

US Brand Names

Xalkori

Action

  • Inhibits receptor tyrosine kinases, including anaplastic lymphoma kinase, hepatocyte growth factor receptor, ROS1, and recepteur d'origine nantais.
Therapeutic effects:
  • Decreased spread of lung cancer and improved survival.
  • Decreased spread of systemic anaplastic large cell lymphoma or inflammatory myofibroblastic tumor.

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics

Absorption: 43% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Mostly metabolized by the liver (CYP3A4/5 isoenzymes); also acts as an inhibitor of CYP3A. 53% excreted in feces unchanged, 2.3% eliminated unchanged in urine.

Half-Life: 42 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown4–6 hrunknown



Patient/Family Teaching

Pronunciation

kriz-OH-ti-nib